Tempus AI Wins $200 Million, Five-Year Spending Commitment From AstraZeneca in Contract Renewal
Tempus AI has locked in another five years of business from AstraZeneca, backed by a $200 million spending commitment.
The two companies signed a fifth amendment to their master services agreement on Nov. 16, according to an 8-K Tempus filed Wednesday. The amendment takes effect Jan. 1, 2027, sets a new five-year financial commitment period and extends the agreement through Dec. 31, 2031.
Under the amendment, AstraZeneca committed to an aggregate $200 million in fees payable to Tempus during the renewal term. That works out to an annual target spend of $40 million across Tempus' existing and future products and services, the filing says.
AstraZeneca also agreed to a minimum of $32 million in fees in each calendar year of the renewal term.
What protects the commitment
If the $200 million total has not been reached by the end of 2031, the renewal term will be extended by one year, through Dec. 31, 2032, to make up the shortfall, according to the 8-K.
AstraZeneca keeps its right to terminate the agreement for convenience at any time. But if it does so before meeting its financial commitments, it will owe Tempus any shortfall against the $200 million, the filing says.
The amendment also extends the strategic collaborator benefits AstraZeneca receives under the existing agreement, which dates to Nov. 17, 2021. Tempus said certain portions of the amendment were omitted from the public exhibit as not material and confidential.
By the numbers
- Total committed fees: $200 million
- Annual target spend: $40 million
- Annual minimum: $32 million
- Renewal term: Jan. 1, 2027, through Dec. 31, 2031
- Possible extension: one year, to Dec. 31, 2032
Sources
- Form 8-K (Item 1.01), Tempus AI, Inc., Fifth Amendment to Master Services Agreement with AstraZeneca AB, filed Nov. 18, 2026, accession 0001193125-26-466240
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence. SI may make mistakes.